Start-date window
Dates reflect registry-reported actual or estimated milestones. Scroll horizontally across all 15 dates, and select a study to jump to its entry.
This edition at a glance
Four oncology studies sit alongside investigations of neurology and devices, obesity and diabetes, immune-mediated conditions, infections, Pompe disease, and engineered cell or gene therapies.
Eleven entries are Phase 2, Phase 2/3, or Phase 3. The remaining four are two Phase 1 studies, a Phase 1/2 study, and a non-phased early-feasibility device investigation. Planned enrollment ranges from four to 390 participants.
Phase mix
Other: 1 Phase 2/3, 1 Phase 1/2, 2 Phase 1, 1 not applicable (device).
Status at compile time
Trials by therapy area
Oncology
4 trialsABBV-706 added to tarlatamab + atezolizumab in first-line extensive-stage small cell lung cancer
First-line ES-SCLC · Sponsor study ID: M26-386 · Registry snapshot last updated 2026-10-26.
Trial design and endpoints
Open-label, randomized; two arms, each receiving a different dose of ABBV-706 with tarlatamab and atezolizumab. Registry states about 80 participants at approximately 25 sites worldwide. Primary endpoints: objective response rate by blinded independent central review (RECIST 1.1) and number of participants with adverse events.
Mechanism and modality
ABBV-706 is described in published early-phase research as an investigational SEZ6-directed antibody–drug conjugate with a topoisomerase-I inhibitor payload. This study combines IV ABBV-706 with IV tarlatamab and atezolizumab; it does not establish efficacy for the combination.
Why it matters
This Phase 2 protocol compares two ABBV-706 dose levels on the same immunotherapy backbone in previously untreated extensive-stage SCLC. Objective response and adverse events are the co-primary measurements; no arm compares this triplet with standard therapy.
Estimated start · Registry-reported investigational study
Mesutoclax + azacitidine versus venetoclax + azacitidine in untreated AML
Newly diagnosed AML · Sponsor study ID: ICP-CL-01210 · Registry snapshot last updated 2026-11-13.
Trial design and endpoints
Randomized, open-label, multicenter. Mesutoclax (ICP-248) + azacitidine versus venetoclax + azacitidine in newly diagnosed AML, age 65 or older, or 18 to under 65 and ineligible for intensive chemotherapy. Primary endpoint: overall survival. Secondary endpoints include CR/CRc rates, MRD-negative CR, event-free survival and transfusion independence.
Mechanism and modality
Mesutoclax (ICP-248) is an investigational oral BCL2 inhibitor; azacitidine provides the combination backbone. The active comparator is venetoclax plus azacitidine. BCL2 inhibition is intended to disrupt an anti-apoptotic survival pathway.
Why it matters
A head-to-head comparison against a venetoclax-based regimen in older or intensive-chemotherapy-ineligible AML, with overall survival as the single primary endpoint. The registry lists one recruiting site, in Hangzhou, China.
Actual start · Registry-reported investigational study
GEM-MeziDEL
Elranatamab + mezigdomide + dexamethasone in relapsed/refractory multiple myeloma
Relapsed/refractory myeloma · Sponsor study ID matches acronym above · Registry snapshot last updated 2026-10-28.
Trial design and endpoints
Open-label, multicenter. Cycle 1: elranatamab + dexamethasone; cycles 2 to 6: elranatamab + mezigdomide + dexamethasone; cycles 7 to 12: elranatamab + mezigdomide. At end of cycle 12, MRD status decides mezigdomide-alone maintenance (MRD-negative) or continued combination (MRD-positive). Primary endpoint: proportion achieving MRD negativity (fewer than 1 tumor cell in 100,000 by next-generation flow).
Mechanism and modality
Elranatamab is a BCMA×CD3-directed T-cell-engaging bispecific antibody; mezigdomide is an investigational cereblon E3 ligase modulator. The protocol sequences them with dexamethasone and adjusts maintenance by measurable residual disease (MRD) status.
Why it matters
An MRD-guided sequence in patients with prior lenalidomide exposure who are refractory or intolerant to it. In MRD-negative patients on mezigdomide maintenance, elranatamab can be added on MRD re-positivity or progression. Prior BCMA bispecific therapy is an exclusion; prior BCMA CAR-T or ADC is allowed after more than 6 months. Sites are in Spain.
Estimated start · Registry-reported investigational study
SAPPHIRE
Subcutaneous versus intravenous dostarlimab + carboplatin-paclitaxel in advanced or recurrent endometrial cancer
Endometrial cancer · Sponsor study ID: 300118 · Registry snapshot last updated 2026-10-19.
Trial design and endpoints
Open-label, two-part. Part 1 (Phase 1b) selects the subcutaneous dose; Part 2 (Phase 3) randomizes participants to subcutaneous or intravenous dostarlimab, each with carboplatin-paclitaxel. Primary endpoints are pharmacokinetic: Ctrough and AUC of dostarlimab. Secondary endpoints include confirmed ORR, PFS, OS, safety and anti-drug antibodies.
Mechanism and modality
Dostarlimab is an anti-PD-1 antibody. This study tests subcutaneous delivery versus intravenous dosing on the same carboplatin–paclitaxel backbone; its primary readouts concern dostarlimab exposure (pharmacokinetics), not a claim of improved survival.
Why it matters
The central question is whether subcutaneous dostarlimab can provide relevant pharmacokinetic exposure relative to IV administration when given with carboplatin–paclitaxel. Efficacy and safety remain important secondary measures.
Estimated start · Registry-reported investigational study
Neurology & devices
2 trialsUblituximab maintenance after efgartigimod induction in myasthenia gravis
Myasthenia gravis · Sponsor study ID: TG1101-MG201 · Registry snapshot last updated 2026-10-29.
Trial design and endpoints
Randomized, double-blind, placebo-controlled. Adults with myasthenia gravis who respond to efgartigimod are studied for ublituximab versus placebo as maintenance. Primary endpoint: time to onset of a clinical worsening event, up to Week 24. Secondary endpoints include TEAEs, ublituximab Cmax, CD19+ B-cell counts and change in MG-ADL at Week 24. Seven U.S. sites are listed.
Mechanism and modality
Efgartigimod reduces circulating IgG by targeting FcRn; ublituximab is an anti-CD20 B-cell-depleting monoclonal antibody. The trial asks whether maintenance after response to efgartigimod delays clinical worsening.
Why it matters
Tests whether a maintenance agent can hold participants who responded to efgartigimod induction, using time to clinical worsening as the primary endpoint over 24 weeks against placebo.
Estimated start · Registry-reported investigational study
RECLAIM
Intracortical microelectrodes to support communication in severe neurologic impairment
Communication neurotechnology · Sponsor study ID: HSC-MS-26-0020 · Registry snapshot last updated 2026-11-12.
Trial design and endpoints
Early feasibility study of the RECLAIM System in adults aged 22 to 65 with severe communication impairment from ALS, locked-in syndrome, or brain injury including stroke. Primary endpoint: safety (number and type of adverse events from implant to one year). Secondary endpoints include word error rate, phoneme error rate, BLEU and BERT scores every three months for two years.
Mechanism and modality
The investigational RECLAIM interface uses intracortical microelectrode recordings from language-related brain networks to decode intended communication. The study is an early feasibility device investigation, not a drug trial.
Why it matters
Four participants, one site (Houston), safety as the primary endpoint. Effectiveness is measured by decoding error rates (word and phoneme) and text-similarity scores against reference sentences. Included for the device category; Phase is N/A.
Estimated start · Registry-reported investigational study
Cardiometabolic
2 trialsSYNCHRONIZE-START
Survodutide initiation strategies in overweight or obesity without diabetes
Obesity, without diabetes · Sponsor study ID: 1404-0127 · Registry snapshot last updated 2026-10-27.
Trial design and endpoints
Open-label, pragmatic. Evaluates initiation strategies for survodutide, including de novo use and switching from semaglutide or tirzepatide. Two groups differ by starting dose and prior use of similar weight-loss medicines. Once-weekly subcutaneous injection with gradual dose increase. Primary endpoint: percent change in body weight from baseline to Week 52.
Mechanism and modality
Survodutide is an investigational dual glucagon/GLP-1 receptor agonist given subcutaneously. The pragmatic program examines how treatment is initiated, including de novo initiation and switching from semaglutide or tirzepatide.
Why it matters
Addresses how a weight-management drug is started in practice, including after other named agents, in adults with BMI of 30 or more (or 27 or more with a weight-related condition) without diabetes. Quality-of-life instruments (IWQOL-Lite-CT, PROMIS) are among the secondary endpoints.
Estimated start · Registry-reported investigational study
SYH2069 injection in type 2 diabetes: dose-finding against placebo and tirzepatide 15 mg
Type 2 diabetes · Sponsor study ID: SYH2069-003 · Registry snapshot last updated 2026-09-01.
Trial design and endpoints
Randomized, double-blind, placebo- and active-comparator-controlled dose-finding study. Four SYH2069 dose groups (40 participants each), four matched placebo groups (10 each) and tirzepatide 15 mg (40). 28-week treatment period. Population: T2DM inadequately controlled on diet and exercise alone or metformin monotherapy. Primary endpoint: change in HbA1c at Week 28.
Mechanism and modality
The registry identifies four dose groups of investigational SYH2069 injection, matching placebo groups and an active tirzepatide 15 mg comparator. A specific receptor target for SYH2069 was not established from the checked study sources.
Why it matters
Places four doses of an investigational injectable beside both placebo and tirzepatide 15 mg in one Phase 2 study, with HbA1c at Week 28 as the primary endpoint. Registry lists a site in Nanjing, China.
Estimated start · Registry-reported investigational study
Immunology
2 trialsDISCOVERY
Afimetoran in cutaneous lupus erythematosus: a seamless Phase 2/3 design
Cutaneous lupus · Sponsor study ID: AFI-CLE-201 · Registry snapshot last updated 2026-11-10.
Trial design and endpoints
Two-stage, operationally seamless, randomized, double-blind, placebo-controlled. Stage 1 compares two afimetoran doses with placebo to select the dose; Stage 2 confirms efficacy and safety. Once-daily oral capsule for 24 weeks, then all participants receive afimetoran for 28 more weeks. Primary endpoints at Week 24: percent change in CLASI-A and CLASI-70 response.
Mechanism and modality
Afimetoran is an investigational oral antagonist of toll-like receptors 7 and 8 (TLR7/TLR8). The two-stage protocol selects a dose before confirmatory assessment versus placebo.
Why it matters
Combines Phase 2 dose selection and Phase 3 confirmatory evaluation under one protocol in cutaneous lupus that is not adequately controlled by antimalarial therapy. The study began on a registry-reported actual date.
Actual start · Registry-reported investigational study
AMETRINE-SC
Subcutaneous afimkibart induction for moderately to severely active ulcerative colitis
Ulcerative colitis · Sponsor study ID: CA46523 · Registry snapshot last updated 2026-10-26.
Trial design and endpoints
Multicenter, double-blind, placebo-controlled. Subcutaneous induction therapy with afimkibart in moderately to severely active ulcerative colitis (modified Mayo Score), ages 16 to 80, after inadequate response, loss of response or intolerance to at least one protocol-specified conventional or advanced therapy. Primary endpoint: clinical remission at Week 12.
Mechanism and modality
Afimkibart is an investigational monoclonal antibody targeting TL1A, a regulator of inflammatory pathways. The trial tests its subcutaneous induction regimen versus placebo in ulcerative colitis.
Why it matters
Advances the anti-TL1A program into subcutaneous induction for ulcerative colitis, with Week 12 clinical remission as the primary endpoint and endoscopic and symptom outcomes as supporting measurements.
Estimated start · Registry-reported investigational study
Infectious disease
2 trialsmRNA-1469 vaccine against Ebola-Bundibugyo virus disease in African participants aged 1 to 65
Ebola-Bundibugyo · Sponsor study ID: mRNA-1469-P102 · Registry snapshot last updated 2026-11-05.
Trial design and endpoints
Observer-blind, placebo-controlled. Primary endpoints are safety: solicited local and systemic reactions (7 days), unsolicited AEs (28 days), medically attended AEs (about 6 months) and SAEs through Day 337. Secondary endpoints: geometric mean of Bundibugyo ebolavirus-specific binding antibodies and seroresponse at Day 29 through Day 337. Registered site: Uganda Virus Research Institute, Entebbe.
Mechanism and modality
The mRNA-1469 vaccine candidate is designed to elicit an immune response against Ebola-Bundibugyo virus. Safety and BDBV-specific antibody responses are assessed; protection against infection is not established by this early-stage study.
Why it matters
An mRNA vaccine candidate for Ebola-Bundibugyo virus disease, studied from age 1 through 65 in African participants. Included at Phase 1 as a novel-modality entry for a filovirus. Prior participation in a filovirus vaccine study is an exclusion.
Estimated start · Registry-reported investigational study
PYOPHANEB
Nebulized bacteriophages for Pseudomonas ventilator-associated pneumonia
Ventilator-associated pneumonia · Sponsor study ID: APHP222819 · Registry snapshot last updated 2026-09-04.
Trial design and endpoints
Double-blind, placebo-controlled. Nebulized anti-P. aeruginosa bacteriophages (GMP) delivered by vibrating mesh nebulizer, in addition to conventional IV antibiotics, versus saline placebo. Primary endpoint: proportion alive and cured at Day 28 without recurrence of P. aeruginosa VAP. Secondary endpoints include ventilator-free and antibiotic-free days, mortality, anti-phage antibodies and resistant Gram-negative carriage. Sites are in France.
Mechanism and modality
The investigational intervention comprises bacteriophages directed at Pseudomonas aeruginosa, delivered by vibrating-mesh nebulization alongside intravenous antibiotics. The comparator uses nebulized saline alongside usual antibiotic therapy.
Why it matters
The registry cites VAP in up to 40% of mechanically ventilated patients with mortality approaching 30%, and two recent randomized trials of adjunctive nebulized antibiotics in Gram-negative VAP that showed no clinical benefit. This study tests nebulized phages as the adjunct instead.
Estimated start · Registry-reported investigational study
Rare disease
1 trialS-606001 long-term extension in late-onset Pompe disease
Late-onset Pompe disease · Sponsor study ID: 2507N1223 · Registry snapshot last updated 2026-10-13.
Trial design and endpoints
Open-label, multicenter extension. Enrolls participants who completed another S-606001 study (for example NCT07123155), including participants whose allocated arm in such a study was terminated by the sponsor. Primary endpoint: treatment-emergent adverse events through Week 96. Secondary endpoints: %FVC, 6-minute walk test, GSGC score and patient-reported outcomes.
Mechanism and modality
S-606001 is being developed as an oral substrate-reduction approach to reduce glycogen synthesis in Pompe disease; the registry also lists enzyme replacement therapy (ERT). This extension primarily measures longer-term safety and tolerability.
Why it matters
Extends follow-up after earlier S-606001 studies to characterize safety and tolerability over 96 weeks; functional and respiratory outcomes are exploratory or secondary. Its original August start estimate was revised to November.
Estimated start · Registry-reported investigational study
Advanced modalities
2 trialsCT204V
In vivo dual-targeting CD19/CD20 CAR-T gene therapy in B-cell malignancies
B-cell malignancies · Sponsor study ID: R1055C00001 · Registry snapshot last updated 2026-11-12.
Trial design and endpoints
Modular, open-label, single-arm, dose escalation and expansion. Phase 1 primary endpoints: AEs/SAEs, dose-limiting toxicities, AESI. Phase 2 primary endpoints: ORR and CR rate per Lugano, best overall response, duration of response and duration of CR. Secondary endpoints include viral vector and CAR transgene levels in peripheral blood and anti-drug antibodies. Prior VSV-G-containing treatment is an exclusion.
Mechanism and modality
An investigational lentiviral vector is intended to generate anti-CD19/CD20 CAR-T cells in vivo, rather than requiring conventional ex vivo CAR-T manufacturing. Long-term safety surveillance is central to this early-phase gene therapy study.
Why it matters
The registry describes CAR-T cells generated in vivo by a lentiviral vector, with follow-up for adverse events up to 15 years. Relapsed or refractory B-cell malignancies; participants must have CD19 and/or CD20 expression.
Estimated start · Registry-reported investigational study
IL-12 genetically engineered myeloid cells (GEMys) in relapsed or refractory solid tumors
Refractory solid tumors · Sponsor study ID: 10002091 · Registry snapshot last updated 2026-11-12.
Trial design and endpoints
Dose escalation/de-escalation (Part A) and expansion (Part B) at the NIH Clinical Center, Bethesda. Autologous CD34+ cells collected by leukapheresis are transduced with a lentiviral vector encoding single-chain IL-12 and truncated EGFR, then differentiated into myeloid cells and infused on Day 0. Depending on dose level, cyclophosphamide and fludarabine are given first. Primary endpoints: recommended Phase 2 dose (Part A); post-treatment tumor IL-12 or IFN-gamma increase versus pre-treatment (Part B).
Mechanism and modality
The protocol uses autologous hematopoietic stem/progenitor-cell-derived myeloid cells engineered to express interleukin-12 (IL-12). It examines safety and tumor-microenvironment measurements following treatment.
Why it matters
Uses an engineered myeloid-cell approach for solid tumors, with tumor biopsies supporting measurement of the local IL-12 signal. The registry now reports a November 4 actual start following several earlier planned-date revisions.
Actual start · Registry-reported investigational study
Signal convergence
What these fifteen records suggest about clinical development approaches; interpretations are limited to this edition's selected studies.
Administration routes as a development variable
Subcutaneous versus IV dostarlimab is evaluated on drug exposure; subcutaneous afimkibart tests induction in colitis; and nebulized bacteriophages test delivery to the infected lung alongside antibiotics.
Comparative design remains consequential
Mesutoclax is tested against a venetoclax regimen; SYH2069 includes placebo and tirzepatide groups; and SAPPHIRE compares two routes of the same antibody. Their primary endpoints differ.
Engineered immune interventions in early phases
CT204V tests in vivo generation of dual CD19/CD20 CAR-T cells, while the NCI IL-12 myeloid-cell study engineers autologous cells to influence the tumor microenvironment. Neither study establishes patient benefit.
Protocol-defined treatment adaptation
The myeloma protocol uses MRD status to guide maintenance treatment, whereas the cutaneous-lupus study selects an afimetoran dose before confirmatory assessment. These are different forms of response- and dose-informed development.
Feasibility and pharmacokinetics before outcomes
The four-participant communication-interface study prioritizes safety and feasibility, while SAPPHIRE prioritizes pharmacokinetic exposure. A Phase label or technological novelty should not be confused with demonstrated efficacy.
Follow every edition of Trial Watch
Study starts, clinical designs and emerging research signals, twice each month.
✓ Source and editorial methodology
Reporting window: November 1 to November 15, 2026 inclusive. Fifteen distinct studies list a day-level start date inside this interval; three are marked actual and twelve are estimated in the latest accessible registry-derived records reviewed on November 16, 2026. Estimated start dates are not evidence that enrollment began.
Each study has two trial-specific links: the corresponding ClinicalTrials.gov record and a checked sponsor study page, National Cancer Institute listing, or registry mirror. Mirrors reproduce ClinicalTrials.gov records and must not be interpreted as independent clinical corroboration. Sponsor protocol identifiers appear in the card data. Scientific context about mechanisms is distinguished from trial outcomes, none of which are implied to establish efficacy.
Exact NCT identifiers were compared with the supplied Edition 20 archive, with no overlap. A full identifier-level comparison against Editions 1–19 was not completed because their complete historical NCT lists were not supplied. All information may change with later registry amendments. Editorial review does not constitute medical, regulatory, or investment advice.
